GlassScriptPhysician profile
Kasey Kindervater
NPI 1700552585
$5,757.22
in general payments reported to CMS, 2019-2025
36 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $1,599 · 2023: $1,249 · 2024: $1,651 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,006.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.61 | 2021-2025 | |
| Novo Nordisk INC | $798.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $594.63 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $512.55 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.86 | 2021-2024 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $327.48 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.22 | 2022-2025 | Trintellix |
| Amgen INC. | $227.36 | 2023-2025 | Repatha, Otezla, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $226.83 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.29 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $145.01 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $143.46 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $120.12 | 2021-2025 | |
| Exact Sciences Corporation | $112.43 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $84.24 | 2021-2025 | Zerbaxa, Recarbrio, Capvaxive |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $74.91 | 2022-2024 | Freestyle Libre, Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $69.17 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $61.10 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $59.20 | 2024-2025 | |
| Mylan Specialty L.P. | $47.10 | 2022-2024 | Yupelri |
| Biogen, INC. | $44.10 | 2025 | Zurzuvae |
| Inogen, INC. | $41.08 | 2022-2023 | Inogen At Home Stationary Concentrator |
| Janssen Pharmaceuticals, INC | $38.20 | 2023-2024 | Spravato |
| Biohaven Pharmaceuticals, INC. | $31.59 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.71 | 2025 | Zoryve |
| Dexcom, INC. | $25.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.68 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $17.13 | 2024 | Quviviq |
| Shield Therapeutics INC | $15.90 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.87 | 2023 | Linzess |
| Amneal Pharmaceuticals LLC | $15.40 | 2024 | Unithroid |
| Nevro Corp. | $14.41 | 2024 | Senza |
| Esperion Therapeutics, INC. | $13.57 | 2021 | |
| Tolmar, INC. | $13.33 | 2024 | |
| Ambu INC. | $13.00 | 2023 | |
| Sanofi-Aventis U.S. LLC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasey Kindervater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.